AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00%

RNV RENERVE FPO [RNV]

Healthcare · Biotechnology · website
$0.09
52wk 0.07 – 0.22
Overall
Value
Growth
Health
Quality
Momentum
Dividend
Price
About RENERVE FPO [RNV]

ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures. It develops NervAlign Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and NervAlign bionic nerve and NervAlign Nerve Graft, an off-the-shelf, ready to use nerve structure for challenging nerve repairs. The company also offers deep dermal tissue product, a deep dermal product used in the repair of reconstructive and cosmetic surgical cases; amniotic tissue product ranges, used to aid the healing of wounds; NervAlign Nerve Conduit Range, a nerve conduit designed to facilitate nerve growth over short gaps between nerve ends; and NervAlign Nerve Guide Matrix for treating more severe nerve injuries, but eliminating the need for patients to undergo additional sural nerve harvesting. The company was incorporated in 2016 and is headquartered in Northcote, Australia.

Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$14.65M
P/E (trailing)
P/E (forward)
EPS (trailing)
-0.03
Dividend yield
Payout ratio
0.0%
Beta
EV / EBITDA
-1.94
Price / Book
2.66
ROE
-74.9%
Operating margin
-1,848.1%
Net margin
0.0%
Total cash
$4.19M
Total debt
$164,299
Current ratio
6.77
Debt / Equity
0.03
Free cash flow
$-3.49M
Avg volume
110,410
Latest annual results (FY ending 30 Jun 2025)
  • Revenue$271.71K
  • Gross profit$244.67K
  • Operating income-$4.45M
  • Net income-$3.73M
  • Diluted EPS-0.03
  • Free cash flow-$3.05M
  • Net debt-$4.75M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $59.53B 14.0
RMD $43.89B 20.4
SIG $34.28B 59.4
FPH $20.25B 52.2
PME $17.21B 73.5
SHL $10.79B 19.7
RHC $10.13B 34.8
COH $7.90B 22.9